Evidence map›Paper›PMID 28705172›Full record

Trial reportBMC endocrine disorders2017

Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss.

Alison J Dawson, Eric S Kilpatrick, Anne-Marie Coady, Abeer M M Elshewehy, Youssra Dakroury, Lina Ahmed, Stephen L Atkin, Thozhukat Sathyapalan

Open access · goldFull text readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC endocrine disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Cannabinoids in Gynecological Diseases.Medical cannabis and cannabinoids · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Alison J DawsonDepartment of Diabetes and Endocrinology, University of Hull, Hull, UK.
Eric S KilpatrickDepartment of Clinical Biochemistry, Sidra Medical and Research Centre, Doha, Qatar.
Anne-Marie CoadyDepartment of Obstetric Ultrasound, Hull & East Yorkshire Women's & Children's Hospital, Hull, UK.
Abeer M M ElshewehyWeill Cornell Medicine Qatar, Research Department, PO Box 24144, Doha, Qatar.
Youssra DakrouryWeill Cornell Medicine Qatar, Research Department, PO Box 24144, Doha, Qatar.
Lina AhmedWeill Cornell Medicine Qatar, Research Department, PO Box 24144, Doha, Qatar.
Stephen L AtkinWeill Cornell Medicine Qatar, Research Department, PO Box 24144, Doha, Qatar. sla2002@qatar-med.cornell.edu.
Thozhukat SathyapalanDepartment of Diabetes and Endocrinology, University of Hull, Hull, UK.
Weill Cornell Medical College in Qatar · QAUniversity of Hull · GBHull and East Yorkshire Hospitals NHS Trust · GBSidra Medical and Research Center · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEvidence suggests that endocannabinoid system activation through the cannabinoid receptor 1 (CB1) is associated with enhanced liver injury, and CB1 antagonism may be beneficial. The aim of this study was to determine the impact of rimonabant (CB1 antagonist) on alanine aminotransferase (ALT), a hepatocellular injury marker, and a hepatic inflammatory cytokine profile.

methodsPost hoc review of 2 studies involving 50 obese women with PCOS and well matched for weight, randomised to weight reducing therapy; rimonabant (20 mg od) or orlistat (120 mg tds), or to insulin sensitising therapy metformin, (500 mg tds), or pioglitazone (45 mg od). No subject had non-alcoholic fatty liver disease (NAFLD).

resultsTreatment with rimonabant for 12 weeks reduced both ALT and weight (p < 0.01), and there was a negative correlation between Δ ALT and Δ HOMA-IR (p < 0.001), but not between Δ ALT and Δ weight. There was a significant reduction of weight with orlistat (p < 0.01); however, orlistat, metformin and pioglitazone had no effect on ALT. The free androgen index fell in all groups (p < 0.05). The inflammatory marker hs-CRP was reduced by pioglitazone (p < 0.001) alone and did not correlate with changes in ALT. The inflammatory cytokine profile for IL-1β, IL-6, IL-7, IL-10, IL12, TNF-α, MCP-1 and INF-γ did not differ between groups. None of the interventions had an effect on biological variability of ALT.

conclusionRimonabant through CB1 receptor blockade decreased serum ALT that was independent of weight loss and hepatic inflammatory markers in obese women with PCOS without NAFLD.

trial registrationISRCTN58369615 (February 2007; retrospectively registered) ISRCTN75758249 (October 2007; retrospectively registered).

Indexed as

Alanine TransaminaseAnti-Obesity AgentsBody Mass IndexCannabinoid Receptor AntagonistsCase-Control StudiesFemaleFollow-Up StudiesHumansHypoglycemic AgentsInsulin ResistanceLactonesLiver DiseasesMetforminObesityOrlistatPioglitazoneAlanine TransaminaseAnti-Obesity AgentsCannabinoid Receptor AntagonistsHypoglycemic AgentsLactonesMetforminOrlistatPioglitazonePiperidinesPyrazolesReceptor, Cannabinoid, CB1RimonabantThiazolidinedionesAltNafldPolycystic ovarian syndromeRimonabant

Identifiers

PMID28705172
PMCPMC5512818
OpenAlexW2735178359

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.